正序生物 is a genetic-disease immunotherapy platform that develops breakthrough therapies based on base editing. The company focuses on treatments for point-mutation–caused genetic diseases and cancer immunotherapy. Its pipeline includes CS-101 and in vivo gene‑editing therapy programs. The firm recently completed an A+ financing that will accelerate CS-101 clinical research and commercialization and support clinical translation of its in vivo therapy pipeline. The round also aims to fund global expansion and efforts to bring gene‑editing products to market. The financing exceeded RMB 100 million and involved multiple strategic and existing investors.

Total raised

$20M

Funding rounds

2

Latest round

Series A

Latest activity

Aug 2024